Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019621 (
Langerhans cell histiocytosis
)
3,250
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The pathogenesis of
Langerhans cell histiocytosis
(
LCH
) is obscure, partly because the events leading to activation of Langerhans-like lesional cells (
LCH
cells) and associated T cells, and the excessive cytokine production by these cells are unknown. The interaction between
CD40
on antigen-presenting cells (APC) like Langerhans cells and CD40 ligand (CD40L) (CD154) expressed by activated CD4+ T cells, is essential for the activation of both the APC and the T cells and results in upregulation of APC functions and initiation of immunoreactivity. The effects of
CD40
-CD40L interaction include increased expression of co-stimulatory and adhesion molecules, proliferation, and production of pro-inflammatory cytokines and proteolytic enzymes, all features of
LCH
. Using immunohistochemistry, we analysed the in situ presence of the co-stimulatory molecules
CD40
and CD40L in 15 fresh frozen biopsies of
LCH
lesions in children. The cells producing these molecules were identified by double staining for CD1a on
LCH
cells and CD3 on T cells. Prominent expression of
CD40
by
LCH
cells and CD40L by T cells was found in all 15 specimens regardless of the source of specimen or characteristics of the patient. The findings of high expression of
CD40
and CD40L in all specimens imply a key role for the
CD40
-CD40L adhesion pathway in the pathogenesis of
LCH
. Since this interaction is an accessible and realistic target for immunotherapy, these findings prompt speculation on the use of blocking antibodies to
CD40
or to CD40L in the treatment of
LCH
.
...
PMID:Abundant expression of CD40 and CD40-ligand (CD154) in paediatric Langerhans cell histiocytosis lesions. 1104 48
Langerhans cell histiocytosis
(
LCH
) consists of lesions composed of cells with a dendritic Langerhans cell (LC) phenotype. The clinical course of
LCH
ranges from spontaneous resolution to a chronic and sometimes lethal disease. We studied 25 patients with various clinical forms of the disease. In bone and chronic lesions,
LCH
cells had immature phenotype and function. They coexpressed LC antigens CD1a and Langerin together with monocyte antigens CD68 and CD14. Class II antigens were intracellular and
LCH
cells almost never expressed CD83 or CD86 or dendritic cell (DC)-Lamp, despite their
CD40
expression. Consistently,
LCH
cells sorted from bone lesions (eosinophilic granuloma) poorly stimulated allogeneic T-cell proliferation in vitro. Strikingly, however, in vitro treatment with CD40L induced the expression of membrane class II and CD86 and strongly increased
LCH
cell allostimulatory activity to a level similar to that of mature DCs. Numerous interleukin-10-positive (IL-10(+)), Langerin(-), and CD68(+) macrophages were found within bone and lymph node lesions. In patients with self-healing and/or isolated cutaneous disease,
LCH
cells had a more mature phenotype.
LCH
cells were frequently CD14(-) and CD86(+), and macrophages were rare or absent, as were IL-10-expressing cells. We conclude that
LCH
cells in the bone and/or chronic forms of the disease accumulate within the tissues in an immature state and that most probably result from extrinsic signals and may be induced to differentiate toward mature DCs after
CD40
triggering. Drugs that enhance the in vivo maturation of these immature DCs, or that induce their death, may be of therapeutic benefit.
...
PMID:Differentiation of Langerhans cells in Langerhans cell histiocytosis. 1156 38
We present the case of a woman with diabetes insipidus with subsequent genital and multiorgan
Langerhans cell histiocytosis
(
LCH
). A monolateral and slightly infiltrated erythematous plaque of the vulva was observed. Hematoxylin and eosin and immunophenotypic studies were performed. The primary antibodies used were monoclonal antibody to S100, CD1a, CD34, HLA-DR, PCNA, CD45Ro,
CD40
, and langerin. The histology of the infiltrates revealed a granulomatous reaction pattern, with extensive aggregates of histiocyte proliferation. The histiocytes, morphologically characterized by a pale staining of cytoplasm surrounding a grooved reniform nucleus, sometimes contained small distinct nucleoli. Lymphocytes, eosinophils, macrophages, and both plasma cells and giant cells typically infiltrated the lesions. Cells CD1a+ and S100+ infiltrated the epidermic and were dispersed over the infiltrates as well as in clusters, and around the vessels. A considerable number of
CD40
-expressing cells were restricted to CD1a+
LCH
cells. The specimen contained a high percentage of langerin+ cells in both the dermis and the epidermis. The clinical manifestations of
LCH
affecting the genital area can be diverse, and in most patients take the form of ulcers or erythematous plaques. Histopathologic examination of the lesion evidences a mixture of Langerhans cell histiocytes (CD1a+, S100+, HLADr+, CD207+, CD 40+), lymphocytes (predominantly helper [CD4] CD 45 Ro+), eosinophils, and macrophages. Each of the cell types produces a "cytokine storm." Many of the cytokines favor recruitment of Langerhans cell progenitors and rescue the Langerhans cell histiocytes from apoptosis.
...
PMID:Clinical and immunohistochemical evaluation of the vulvar Langerhans cell histiocytosis. 1907 26